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Minimizing Infant Exposure to and
Risks from Medications while
Breastfeeding
The advantages ofbreastfeeding to the mother and newborn are many. Lactating mothers frequently
ask about the safety of taking medications and the risk to their newborn. It is well established that
all drugs are excreted into breast milk. However, most medications appear in only small amounts
within the breast milk. With the availability of numerous resources on drug use while breastfeeding,
a medication can be identified as contraindicated or compatible with breastfeeding. By understanding the anatomy of the breast, principles oflactation, and drug passage into breast milk, an approach
to minimize the transfer of the medications in the breast milk to the newborn can be developed. The
plan should usually support and encourage the mother to continue to breastfeed her infant. Key
words: breastfeeding, breast milk, drugs, lactation, medications
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O MATTER whether the agent is an
over-the-counter medication or one prescribed by a health care provider, most medications are detected in breast milk. The
presence of a medication in breast milk may
be inferred as a potential hazard to the
infant, although only 1% to 2% of total
maternal intake is likely to be found. 1 Therefore the primary consideration in maternal
drug therapy is the risk to the nursing infant,
rather than the mere presence of the medication in the breast milk. Based on the many
advantages of breastfeeding, the benefit of
this physiologic process in the majority of
cases far exceeds the potential risk. Few
medications are truly contraindicated for
the breastfeeding mother. While maternal
medication therapy may be viewed as a
reason for stopping breastfeeding, it usually
should not be.
PHYSIOLOGY OF LACTATION

Understanding breast anatomy and the
physiology oflactation is essential to com-

prehending the complex interaction occurring with maternal medication use during
breastfeeding.

thelial cells. The two-cell layer is surrounded by a layer of basal lamina and
delimiting fibroblast. 2

Breast anatomy

Initiation and maintenance of lactation

The basic structure of the breast is the
alveolus, or acinus, which is composed of
secretory cells where the terminal ductules
end. Each cluster of secretory cells of the
alveolus is surrounded by a contractile unit
of myoepithelial cells responsible for ejecting milk into the ductules (Fig 1). Each
terminal ductule then merges into the larger,
lactiferous, or mammary, duct. Lactiferous
ducts widen into the ampullae or lactiferous sinuses located behind the nipple and
the areola. The lactiferous sinus opens at
the nipple (Fig 2). It is the compression on
the lactiferous sinuses by the newborn's
suck that causes breast milk to be expressed.
Except for a small segment at the nipple
opening where squamous epithelium lines
the duct, the entire duct system is lined by
a two-cell layer. The inner epithelial cell
layer along the luminal side is surrounded
by a spindled, interrupted layer of myoepi-

During pregnancy, maternal prolactin,
progesterone, and estrogen levels increase.
Prolactin is the major hormone responsible
for lactation initiation and causes an increase
in the number of secretory cells and prolactin
receptors. During pregnancy, high levels of
progesterone inhibit prolactin action. After
birth the delivery of the placenta triggers a
prolactin surge while progesterone and estrogen levels fall. The prolactin activates the
secretory cells of the alveolus to manufacture
breast milk. This initial milk production occurs whether a newborn breastfeeds or not.
Afterward the nursing newborn's suckling
stimulates the afferent nerves to release prolactin which causes milk synthesis (Fig 3).
Prolactin levels remain elevated as long as
breastfeeding occurs. With each breastfeeding
episode there is a prolactin burst. The prolactin burst is vital in maintaining milk volume,
rather than a constantly elevated prolactin
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Fig 1. Schematic diagram of the myoepithelial cells around the ductule opening into alveolus.
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Fig 2. Schematic diagram of the breast.

level. At the same time, the posterior pituitary gland releases oxytocin, which mediates the contraction of myoepithelial cells
around the alveolus, causing milk ejection
into the larger terminal ductule (Fig 4). Milk
is moved along to the lactiferous sinuses,
becoming available to the newborn via the
openings in the nipple.

Breast milk composition
At the time of delivery, colostrum is
present within the maternal breast. Colostrum is high in proteins and low in sugar
and fat. As a result, colostrum is easy for
the newborn to digest. Within 2 to 3 days
after delivery, the secretion of milk be-
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Fig 3. Release and effect of prolactin.

gins. The changes in milk composition
continue for 10 days, when "mature milk"
is established. Mature milk is higher in
proteins and fat, thus higher in caloric
content.

PASSAGE OF DRUGS INTO BREAST

MILK
A medication given to a lactating mother
follows an intricate route to the infant. The
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Fig 4. Release and effect of oxytocin.

drug may be partially inactivated in the
mother's liver, excreted in her urine, or distributed and protein bound. As a result, the
free serum concentration in the mother is

frequently low. When the medication is absorbed by the infant, it continues to undergo
metabolism, renal excretion, protein binding, and tissue distribution. In addition, the

amount and frequency of breastfeeding will
affect the concentration of the drug. Thus
there are many factors that influence the
passage of drugs into breast milk. These factors include the drug itself, maternal factors,
infant factors, and the blood-milk barrier.
Drug factors

The drug's characteristics determine the
amount of it that will be transferred into the
breast milk. These characteristics include the
molecular weight of the drug, the proportion
of the drug that is bound to plasma and milk
proteins, the solubility of the drug in lipids
and in water, the proportion of the drug that
is ionized or nonionized, the pH of the drug,
and the half-life of the drug.

Molecular weight
The mammary epithelium membrane acts
as a semipermeable lipid barrier. Small
pores permit drugs with a low molecular
weight to pass through. The lower the molecular weight of the drug, the easier the
drug passes through to the milk. Drugs with
a molecular weight of more than 200
kilodaltons, such as heparin and insulin,
are unable to cross the alveolar membrane. 3

Protein binding
Only the fraction of the medication in the
maternal plasma that is not protein bound
can leave the maternal circulation, diffuse
across the alveolar membrane, and accumulate in the breast milk. Casein, alpha-lactalbumin, lactoferrin, and immunoglobulinA
(IgA), the main milk proteins in breast milk,
do not bind drugs well. 4 More than half of

Drugs with a molecular weight of
more than 200 kilodaltons, such as
heparin and insulin, are unable to
cross the alveolar membrane.

the plasma protein in the maternal circulation is albumin, a major drug-binding protein. The high protein binding in the maternal plasma effectively restricts many drugs
to the plasma compartment and are not
transferred into the breast milk. Thus highly
protein-bound medications, such as phenytoin (Dilantin), are excreted into the breast
milk in small amounts.

Lipid solubility
The more lipid soluble the drug, the
greater the quantity and the faster the transfer into breast milk. Lipid-soluble drugs
cross cell membranes more rapidly by dissolving in the lipid bilayer. In contrast, a
water-soluble drug must cross the cell membranes through the pores. Thus drugs with
a low lipid solubility diffuse slower into
the breast milk. 5 For example, diazepam
(Valium), which is very lipid soluble, rapidly accumulates in the breast milk. 6

Drug pH ionization
While average plasma pH is 7.4, the mean
pH of breast milk is 7.2, which is significantly lower. 7 Weak acids are ionized in the
maternal plasma, decreasing their passage
into the breast milk. Weak bases are
nonionized in the maternal plasma, increasing their lipid solubility and transfer into
breast milk. At the lower pH of breast milk
some weak bases will become ionized, preventing diffusion back across the membrane.
As a result, the drug molecule becomes
trapped in the breast milk and may achieve
a higher concentration than otherwise predicted. Conversely, drugs that are more acidic
tend to concentrate in the maternal plasma
and do not readily transfer into breast milk.
For example, erythromycin and antihistamines, drugs that are weak bases, would be
more likely to cross the membranes from
plasma into breast milk than barbiturates
and penicillins, drugs that are weak acids. 8

Half-life of the drug
The half-life of a drug is determined by
the drug's volume of distribution and clearance. Half-life varies greatly from one drug
to another. For example, the half-life of
ampicillin is 1 hour, Coumadin about 36
hours, and digoxin approximately 1 week. 9
A drug with a short half-life will have
plasma concentrations that fluctuate the
most and must be taken more frequently
than a drug with a longer half-life to maintain therapeutic levels. Thus the longer the
half-life of the drug over time, the greater
the accumulation will be in the mother, in
the breast milk, and in the infant.
Maternal factors

Several maternal factors influence the
plasma level of a drug in the breast milk.
These factors include the dose, frequency,
timing and route of administration, the
mother's health, breast milk composition,
and breast anatomy.
Dose

The dose of the medication is one factor
that determines how much of the drug will
enter the maternal circulation and the breast
milk. The higher the dose, the more drug
passes into breast milk. Thus the recommendation to use the lowest dose needed
decreases the amount of a drug that will
pass into the breast milk.

Route of administration
The route of administration determines
how much of the medication will enter the
maternal circulation and, therefore, the
breast milk. The medication may be administered through one of several routes,
such as intravenously, intramuscularly,
orally, topically, or by inhalation. The
intravenous (IV) route allows a drug to
transfer into the breast milk without consideration of an absorption factor. The

amount of a drug that enters the plasma
following all other routes of administration is decreased compared with IV dosing. Thus breast milk levels will be highest
following IV dosing compared with other
routes.

Timing of medication
Breast milk is manufactured while the
infant is suckling. The breast stores only a
small amount of breast milk between
feedings. Thus the timing of a drug dose in
relation to breastfeeding influences how
much of the drug will appear in the breast
milk. For example, if the infant is
breastfeeding when the maternal serum drug
level is peaking, the amount of a drug that
transfers to the breast milk is higher than if
her serum level is at a trough. In addition,
the blood flow to the breast increases when
the breasts begin to lactate. A peaking drugserum level combined with an increase in
mammary blood flow will deliver a higher
amount of the drug to the milk. Conversely
a drug taken immediate!y after breastfeeding
has the maximum time to clear the maternal
blood. However, with a newborn who is
breastfeeding more than eight times a day,
trying to time the dose is nearly impossible.

Maternal health
The mother's health is another factor of
drug transfer into the breast milk. If the
mother's ability to clear the medication is
impaired, such as by poor liver or kidney
function, a greater quantity can accumulate
in the breast milk and be ingested by the
infant.

Composition of breast milk
The composition of the maternal breast
milk also affects the ability of the drug to
cross the plasma into the milk. Colostrum
is high in proteins and low in lactose and
fat. As mature milk develops, this ratio is

reversed. As the protein, fat, water, and
sugar content changes, the drug transfer
mechanisms change. Lipid-soluble drugs
may concentrate in the breast milk fat. The
usual amount of fat in breast milk is low
when compared with the total milk volume. As a result, the amount of a drug that
reaches the infant is probably small with
mature milk.

Breast anatomy
Immediately after birth, the spaces between the myoepithelial cells ofthe alveolus are large and allow the passage of
larger plasma proteins like IgA. However,
these spaces close to become small pores
within a week. As a result, the passage is
restricted to lower molecular weight, water-soluble, nonelectrolytes.
Blood-milk barrier

A drug in the mother's blood stream must
first pass out of the blood capillary into the
connective tissue surrounding the secretory lobes. To pass through the alveolar
lumen, the drug must penetrate the membranes of myoepithelial cells and walls of
the secretory cells lining the alveolus (Fig
5). This penetration is accomplished by
either diffusion through the lipid portion
of the membranes or through protein chan-

Maternal
Circulation

Maternal
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nels in the membranes. Passive diffusion of
drugs is most common. A secondary route
is to pass through the alveolar lumen via
small intercellular clefts, bypassing the
secretory and myoepithelial cells.
Infant factors

Infants are continually growing and maturing, especially the premature infant.
Thus what adversely affects the newborn at
one point in time may not be an issue a
week or a month later. There are several
infant factors that influence the plasma
drug level in the infant acquired from the
breast milk. These factors include absorption, protein binding, hepatic metabolism,
renal excretion, and frequency and volume
of feedings.

Absorption
In infants, gastric emptying time is delayed and intestinal absorption is irregular,
resulting in delayed absorption of some
drugs. In addition, the infant has a higher
gastric pH during the first few days of life,
probably allowing gastric absorption of
weak bases that would not occur later. 10
Other factors that can influence drug absorption are the infant's gastrointestinal
flora and reduced amounts of bile salts and
pancreatic enzymes.

Myoepithelial
Layer

Alveolus Ductule

Drug
Infant
----------------------------------------------------------------------------------------------------------------------------------- >
Fig 5. Simplistic diagram of the blood-milk pathway.

Protein binding
Less protein and less binding per unit
protein in the infant compared with the
adult results in increased clearance ofhighly
protein-bound drugs by glomerular filtration. This appears to compensate for the
decrease in clearance observed due to immature glomerular function. The infant
approaches adult values for protein binding by 10 to 12 months of age.U

Renal excretion
Glomerular filtration and tubular secretions are both underdeveloped in the neonate at birth. Immediately following delivery there is a rapid maturation of the kidneys.
By 2 to 3 days postdelivery, the glomerular
filtration rate (GFR) values are three times
those of the first day of deliveryY As a
result, a term newborn will have a GFR of
one third of adult values. In contrast, a
preterm newborn born at 28 weeks will have
only a GFR of 10% of adult values. 13 The
GFR approximately doubles during the first
2 weeks after delivery, reaching adult GFR
values between 2 to 5 months of age. 14
Tubular development lags behind glomerular development. Functional tubular
maturation is not reached until7 to 9 months
of age. 15

Metabolism
Hepatic enzymes responsible for the
metabolism of exogenous and endogenous
compounds mature at varying rates. For
example, phenytoin (Dilantin) is metabolized at adult rates within 1 to 2 weeks of
delivery. However, theophylline metabolism in the infant does not reach adult
capacity until 1 year of age. 16
Conjugation capacity of the newborn is
poor and frequently variable. The impaired
conjugation of bilirubin is one factor contributing to high unconjugated bilirubin
concentrations in the newborn. 17 A healthy,

term newborn will not need to have close
monitoring of bilirubin levels if the mother
is taking sulfamethoxazole-trimethoprim
(Bactrim) and is breastfeeding. However, if
the newborn is ill, stressed, premature, or
has hyperbilirubinemia, an alternative
medication for the mother should be recommended as it competes with bilirubin
for albumin-binding sites. As a result, there
is an increase in free bilirubin in the plasma.
Other metabolic reactions are also reduced. For example, esterase activity is
approximately 25% of an adult level in
newborns born 4 to 7 weeks early. This
increases to 33% at term, but does not
approach adult capacity until after 1 year .16

Frequency and volume of feedings
The frequency of breastfeeding and volume ofbreast milk must be considered. The
infant that is breastfeeding only once or
twice a day and taking solids and juices
consumes much less than the neonate who
is breastfeeding eight times or more a day
and not taking any solids.
STRATEGIES TO MINIMIZE INFANT
EXPOSURE AND RISK TO DRUGS
~EBREASTFEEDUNG

Often a mother will be instructed to stop
breastfeeding when a drug is prescribed or
recommended. This recommendation is
usually unjustified and reflects a lack of
knowledge regarding drugs and breast feeding. The following strategies were developed from the WellStart/The San Diego Lactation Program. 19 The goal is to minimize
the infant's exposure to drugs in the breast
milk. These strategies should be used with
available information on the specific drug or
drugs being considered for the lactating
mother, such as the American Academy of
Pediatrics (AAP) Committee on Drugs statement on The Transfer of Drugs and Other
Chemicals into Human Milk. 20

Essential medication
Often the medication is nonessential.
Thus the nurse should question the mother's
need for the drug. For example, recommend a single-cold product to treat only
one or two symptoms, rather than a
multicold product.
Delayed therapy
An elective surgery may be postponed until after the mother has stopped breastfeeding.

Established history
Little or no information on a newer drug
on the market may be available regarding
the safety or pharmacokinetics for the breastfeeding mother. An older drug may provide
more reassurance as to the risks to the infant.
Poor passage into milk
Within a class of drugs, there may be a
wide amount in the degree of drug that
passes into breast milk. Reviewing the list of
available drugs to identify one that is poorly
transferred into breast milk and has minimalactivitywouldgreatlyreducetheinfant's
exposure. If the mother needs a mild analgesic, the list includes acetaminophen, aspirin, and ibuprofen. Of these three, acetaminophen and ibuprofen are preferred to
aspirin. Acetaminophen rapidly enters the
maternal circulation. The amount of acetaminophen in the breast milk, however, is
very small. Ibuprofen does not cross into
breast milk. In contrast, aspirin crosses into
breast milk and is slower to be eliminated
from the milk than the plasma. A cumulative effect from aspirin could have consequences for the nursing infant.
Alternative routes of administration
Attempting to decrease the maternal
blood-drug concentration will lower the
amount of a drug in the breast milk that is

?assed on to the infant. For example, an
mhaled bronchodilator will minimize the
amount of drug passed into breast milk
compared to an oral agent for asthma.
Milk production
Certain drugs decrease prolactin levels
and thereby decrease milk production (Table
1). As a result, the mother is forced to stop
breastfeeding earlier than planned or the
need for supplementation with formula results or both. If the mother has resumed
taking oral contraception, she should take
an oral contraception that contains only
progestin without estrogen. Estrogen decreases prolactin levels, thus decreasing
breast milk volume and duration of lactation. In contrast, progestin has no effect on
breast milk production or duration of lacta~on. However, most recommend that progestin-only oral contraception therapy be started
only after breastfeeding is well established,
usually after 6 weeks.
Peak drug concentrations
When possible, coordinate drug-dosing
times with nursing times to avoid
breastfeeding when peak drug concentrations are present in the maternal serum. This
works best with drugs that have a short halflife, such as ampicillin. Peak drug concentration of oral medications occurs 1 to 3
hours after the dose. If the mother can nurse
just before the dose, this will reduce the
amount that the infant will receive. This
plan does not work for the newborn who is
nursing frequently or is on an irregular sched-

Coordinate drug-dosing times with
nursing times to avoid breastfeeding when peak drug
concentrations are present in the
maternal serum.

Table 1. Medications that decrease breast milk volume
Generic name

Alcohol (excessive)
Androgens
Antihistamines
Apomorphine
Barbiturates
Bromocriptine
Erocryptine
Estrogens
Levodopa
Phenelzine
Prostaglandin E2
Pyridoxine
Tranylcypromine

Trade name

(Numerous)
(Numerous)
Apomorphine
(Numerous)
Parlodel
Ergocryptine
(Numerous)
Dopar, Larodopa
Nardil
Vitamin B6
Parnate

Source: Adapted from Riordan]. Drugs and breastfeeding. In: Riordan J, Auerbach KG. Breastfeeding and Human
Lactation. Copyright© 1993 Jones and Bartlett.

ule. In addition, encourage the mother to
take a nonextended- rather than an extendedrelease form of the medication.
Infant sleep period
With long-acting drugs that can be given
once a day, maternal administration just
before the infant's longest period of sleep
may help to reduce the amount of drug
transferred into the breast milk. For example, warfarin (Coumadin) should be
given after the last feeding of the day.
Temporary withholding of breastfeeding
Sometimes taking a drug that would be
harmful to the infant is necessary for the
mother. If known in advance to drug
therapy, the mother may decide to pump
extra breast milk that can be frozen for
later use or temporarily to substitute formula or both. While the mother is on this
medication, she will need to use a piston
electrical breast pump to maintain lacta-

tion and must then discard the expressed
milk. If the mother is given metronidazole
(Flagyl) to treat trichomoniasis,
breastfeeding should be interrupted for 24
hours and an alternative feeding method
should be used. 21
If the mother needs radioactive pharmaceutical, she must temporarily stop
breastfeeding. The mother should be encouraged to inform the nuclear medicine physician before the diagnostic study that she is
breastfeeding and of her desire that a radionuclide with the shortest half-life in breast
milk be used. The mother will need to use the
piston electrical breast pump to maintain her
milk supply, but should discard all her expressed milk for the required time that the
radioactivity is present in the breast milk.
This may vary from 1 day to 2 weeks. 22
Discontinuation of nursing
Usually it is not necessary to stop nursing
completely when taking a drug. However, a

Table 2. Drugs that are contraindicated during breastfeeding
Generic name

Reported sign or symptom in infant or effect on lactation

Bromocriptine
Cyclophosphamide

Suppresses lactation
Possible immune suppression. Unknown effect on growth or
association with carcinogenesis. Neutropenia.
Possible immune suppression. Unknown effect on growth or
association with carcinogenesis.
Possible immune suppression. Unknown effect on growth or
association with carcinogenesis.
Vomiting, diarrhea, convulsions.
1/3 to 1/2 therapeutic blood concentrations in infants.
Possible immune suppression. Unknown effect on growth or
association with carcinogenesis. Neutropenia.
Anticoagulant. Increased prothrombin and partial thromboplastin time in one infant (not used in United States).

Cyclosporine
Doxorubicin
Ergotamine
Lithium
Methotrexate
Phenindione

Source: Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into
human milk. Pediatrics. 1994;93:137-150.

few drugs require that the mother stop
breastfeeding due to the toxicity for the
infant. (See Table 2).
SOURCES OF INFORMATION

Several reviews on drug use during
breastfeeding have been published. However, the AAP Committee on Drugs has a
statement that is of particular importance. 23
This statement is invaluable, as the AAP is
considered an authority on the transfer of
drugs into breast milk. A health care provider may be persuaded to continue to
allow a mother to breastfeed when the
drug is listed as safe by the AAP. However,
the list is not without problems. The list
lacks differentiation of whether the newborn is premature, full term, or an infant;
data on the effect of the drug on lactation;
and data on comparisons within drug
classes.
Drugs in Pregnancy and Lactation is a
detailed reference book that compiles the

research literature and the AAP recommendations.24 This book is available for
less than $100. The most detailed source is
Drugs and Human Lactation, compiled by
the World Health Organization. 25 The summarized qualitative and quantitative aspects are based upon scientific published
data. Unfortunately the cost may be prohibitive at more than $250.
Many communities have drug information centers with hotlines that disseminate information on issues related to drug
therapy. The goal of the drug information
centers is to present accurate and unbiased information on patient-related problems with drug therapy. There are three
different types of drug information centers: university affiliated, usually with a
college of pharmacy; hospital affiliated,
usually with a department of pharmacy;
and pharmaceutical-industry affiliated.
For inquiries specific to drug use in lactation, the drug, dose, and duration of therapy
for the mother are needed. In addition,

specific information regarding the infant
is needed, such as the age and well-being
of the infant. The caller should have as
much information as possible when calling the drug information center. Many
drug information requests require time to
investigate.
Some drug information centers restrict
their services to health care professionals,
a specific health care facility, or even a
geographic area. Thus not all drug information centers are able or have the capacity to
handle requests from outside their institutions. One should identify the closest drug
information center available that will provide the needed service. A comprehensive
list of drug information centers is available
in an annual pharmacists' reference known
as the Drug Topics Red Book. 26
A "fax-on-demand" service for information on drugs in breast milk is available for
a fee. Lactation Fax Hotline is a service that
originated from a computerized database
on information on drugs in breast milk. 27
After punching the drug selection number(s)
from Medications in Mother's Milk into a
push button telephone, the documents are
received within minutes from the fax machine 24 hours a day, 7 days a week. The
business number for the service is 1-800378-1317.

The drug profile includes the generic
and brand name(s), pharmacologic category, AAP compatibility assessment, a
summary of the drug's normal
indication(s), propensity to distribute in
breast milk, references, and pharmacokinetic parameters. This information is usually summarized as a one-page document.
The documents can be faxed directly to
the subscriber of the serv-ice or to someone else, such as a lactation consultant or
pharmacist, anywhere in the world as long
as the subscriber is within the United

States. This easy-to-use service is
affordably priced: $10 registration fee for
the first 10 faxes, then $1 per selection.
There are, however, a few shortcomings
to the service. At the bottom of each page,
six pharmacokinetic parameters (adult
half-life, pediatric half-life, oral
bioavailability, time-to-peak, milk: plasma
ratio, and protein binding) are listed. These
are useful if one is familiar with the terms.
However, no explanation comes with the
terms to assist in determining what each
term means or how it plays a significant
role in the breast-fed infant. On some medications, the pharmacokinetic parameter
section is empty. One must assume that
there are no data available. In addition,
one must have the book, Medications in
Mother's Milk, to identify what drug information is desired.

•

•

•

Breastfeeding has many well-established
benefits for the mother and infant. Nursing mothers frequently ask questions regarding the safety of a medication. Basically most drugs do pass into breast milk,
most appearing only in small amounts.
Very few drugs, however, are truly contraindicated for the nursing mother. The
mother's need for a medication is not a
reason to stop breastfeeding. There are
many ways to obtain information on drug
use during lactation. After obtaining information on the specific drug(s), the
mother should be assisted to use strategies
to minimize her infant's exposure and risk
to the medication while breastfeeding. By
understanding the principles of drug passage into breast milk and evaluating the
mother's needs, a plan can usually be
developed that allows the benefits of
breastfeeding.
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